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Abstract
Objectives To estimate rates of discontinuation and restarting of statins,
and to identify patient characteristics associated with either
discontinuation or restarting.
Design Prospective open cohort study.
Setting 664 general practices contributing to the Clinical Practice
Research Datalink in the United Kingdom. Data extracted in October
2014.
Participants Incident statin users aged 25-84 years identified between
January 2002 and September 2013. Patients with statin prescriptions
divided into two groups: primary prevention and secondary prevention
(those already diagnosed with cardiovascular disease). Patients with
statin prescriptions in the 12 months before study entry were excluded.
Main outcome measures Discontinuation of statin treatment (first 90
day gap after the estimated end date of a statin prescription), and
restarting statin treatment for those who discontinued (defined as any
subsequent prescription between discontinuation and study end).
Results Of 431 023 patients prescribed statins as primary prevention
with a median follow-up time of 137 weeks, 47% (n=204 622)
discontinued treatment and 72% (n=147 305) of those who discontinued
restarted. Of 139 314 patients prescribed statins as secondary prevention
with median follow-up time of 182 weeks, 41% (n=57 791) discontinued
treatment and 75% (43 211) of those who discontinued restarted.
Younger patients (aged ≤50 years), older patients (≥75 years), women,
and patients with chronic liver disease were more likely to discontinue
statins and less likely to restart. However, patients in ethnic minority
groups, current smokers, and patients with type 1 diabetes were more
likely to discontinue treatment but then were more likely to restart,
whereas patients with hypertension and type 2 diabetes were less likely
to discontinue treatment and more likely to restart if they did discontinue.
These results were mainly consistent in the primary prevention and
secondary prevention groups.
Conclusions Although a large proportion of statin users discontinue,
many of them restart. For many patient groups previously considered
as “stoppers,” the problem of statin treatment “stopping” could be part
of the wider issue of poor adherence. Identification of patient groups
associated with completely stopping or stop-starting behaviour has
positive implications for patients and doctors as well as suggesting areas
for future research.
Introduction
There has been a marked increase in statin prescribing over the
past 10 years, both for patients with cardiovascular disease and
for those at high risk of developing it.1 In the United States2 and
United Kingdom,3 recent guidelines have lowered the threshold
for consideration of statins in patients without cardiovascular
disease from a 20% risk of developing cardiovascular disease
at 10 years4 to a 10% risk at 10 years. 2 3 These changes were
based on recommendations from the Cholesterol Treatment
Trialists meta-analysis (2012)5 and a revised Cochrane review
(2013).6
Concerns have been raised about the balance of harms and
benefits of statins, especially for the larger number of statin
users with lower absolute risk of cardiovascular disease.7-9
Although observational studies have examined the pattern of
uptake of statins10 11 and of unintended effects from statin use,12-14
it is unclear which patient characteristics affect discontinuation,
in what ways, and by how much. Papers have examined risks
of non-adherence and discontinuation, but study designs were
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inconsistent in terms of patient selection, definition of
discontinuation, and availability of possible risk predictors, thus
creating challenges for meta-analyses.15 16 Results from a few
investigations of restarting suggested that most discontinuers
eventually restarted, but these studies were all based on data
only up to 2008. 17-19 One study investigated factors associated
with restarting, but had only a limited number of factors
available and was not representative of a general population.18
We have, therefore, undertaken a study using a large primary
care database in the UK to determine rates of discontinuation
and restarting in statin treatment, and to identify those patient
characteristics associated with discontinuation and those
associated with restarting.
Methods
Study design
This study design has been fully described elsewhere.20 In
summary, in October 2014, we extracted information from 664
UK general practices contributing to Clinical Practice Research
Datalink (CPRD), identifying an open cohort of patients aged
25-84 years who started statin treatment (the entry date) between
1 January 2002 and 30 September 2013. Patients were excluded
if they had less than one year of medical records before or after
the entry date, or had statin prescriptions in the 12months before
entering the study. Patients having only one statin prescription
during the study period were excluded from the main cohort,
being regarded as non-users of statins in the main analyses.
Patients were censored if they died or left the practice. Patients
without cardiovascular disease at the entry date formed a
primary prevention group. If any patients developed
cardiovascular disease, they left the study at the date of their
diagnosis. Patients diagnosed with cardiovascular disease before
or at the entry date formed a secondary prevention group.
Outcomes
The discontinuation outcome was defined as the first 90 day
gap after the estimated end date of a statin prescription, with
outcome date as the estimated end date. This 90 day exposure
window has been used in previous studies based on routinely
collected data in primary care.12 21 To identify patients who
restarted statins after temporarily stopping, we ran a second
analysis on those who had discontinued. The restarting outcome
was defined as the first statin prescription found after the period
of discontinuation, with outcome date as the date of this
prescription.
Exposure and covariates
Five statins commonly prescribed in the UK were considered:
simvastatin, atorvastatin, fluvastatin, rosuvastatin, and
pravastatin. Daily dose was expressed in potency units to exceed
30% reduction in low density lipoprotein levels (20 mg of
simvastatin, 10 mg of atorvastatin, 80 mg of fluvastatin, 5 mg
of rosuvastatin, and 40mg of pravastatin).22The dose was further
categorised as less than one potency unit, one unit, two units,
and three or more units. We calculated cumulative duration of
exposure as the period between the first prescription date and
the estimated end of the final prescription.
To characterise patients who discontinued, did not discontinue,
or restarted the treatment, we used several factors:
• Demographics (age, sex, ethnicity, and socioeconomic
status)
• Clinical values (smoking status, body mass index, systolic
blood pressure, total cholesterol:high density lipoprotein
ratio)
• Chronic diseases (rheumatoid arthritis, chronic renal
disease, liver disease, atrial fibrillation, treated
hypertension, cancer, heart failure, diabetes and dementia)
• Genetic characteristics (family history of premature
coronary heart disease and diagnosis of familial
hypercholesterolaemia)
• Use of other treatments.
Medication factors included specific drugs related to
cardiovascular treatment (aspirin and anticoagulants), and the
number of other treatments with systemic effect (tablets or
injections) associated with chapters in the British National
Formulary.23 The description of patients in the primary
prevention group also included their 10 year cardiovascular risk
calculated by the QRISK2-2014 score.
Records for covariates were considered if they were recorded
before or at the entry date. To achieve more complete records,
we extracted ethnicity information from both the CPRD and the
link to Hospital Episode Statistics. Deprivation was measured
by the Townsend score (divided into five equal groups). Scores
based on the patient’s residential area were available for only
62% of patients; therefore, for the main analysis, we used the
general practice area deprivation scores. In an additional analysis
on this subgroup of 62%, we used patient based scores.
Statistical analysis
The analysis was run separately for the primary and secondary
prevention groups. We calculated the incidence of
discontinuation during follow-up by dividing the number of
incident stoppers by the number of person years. Patients were
considered long term users rather than short term users if they
used statins for more than a year. Discontinuation was pictorially
described by Kaplan-Meier curves.
To investigate the associations between the covariates at study
entry and the risk of statin discontinuation, we used multivariate
Cox regression analysis. Age, sex, ethnic group, practice based
deprivation group, calendar year, type and dose of statin at the
study entry, chronic diseases, clinical values, genetic
characteristics, and use of other treatments were all entered
together in the multivariate model, clustered by general practice.
We checked the proportional hazards assumption for included
variables, and the only variable violating the
assumption—dementia—was included as a stratifying factor.
Continuous variables were assessed for non-linear risk
association and were included into the model as fractional
polynomial terms.
To account for missing values, we used multiple imputation to
create five imputed datasets with multiple chained equations,
applying Rubin’s rules to combine effect estimates and standard
errors.24The imputationmodel included all potentially important
covariates, statin stopper status, years of records, and cumulative
exposure to statins.25 To test our assumption that data were
missing at random, we ran a sensitivity analysis using only
records with complete data.
The second analysis of discontinuers to identify restarters used
the same analytical approach as that used to identify the
discontinuers. The model included the same covariates apart
from statin type and dose use at baseline, which were replaced
by statin type and dose at the time of discontinuation. The
multivariate analysis of discontinuers to investigate restarting
was not described in the protocol and was added for consistency.
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Additional analyses
We conducted all six additional analyses using the same design
with the exception of one with a changed definition of outcome.
The first two analyses addressed possible differences between
patients who discontinued within the first year and those who
stayed on statin treatment for more than a year. They comprised
one analysis of factors associated with statin discontinuation
restricted to the first year of follow-up with patients censored
at this point, and one analysis restricted to patients still taking
statins at one year and analysing factors associated with statin
discontinuation during the remaining follow-up time.
In the third additional analysis, we truncated the follow-up of
the cohort at five years to reduce the effect of possible changes
in baseline variables. In the fourth analysis, we included all
patients—even those with only one prescription.We conducted
the fifth analysis to facilitate comparison with studies defining
discontinuation as a period substantially longer than 90 days.19 26
In this analysis, we selected patients with at least two years of
follow-up, defining discontinuation as the first 12 month gap
after the estimated end date of any prescription, and included
an analysis of restarting for discontinuers. In the sixth analysis,
we did not assume that people without recorded ethnicity were
white, adding a category for not recorded.
Patient involvement
In this study, patients were not involved in setting the research
question or outcome measures, or in the design or
implementation of the study. However, the patient reviewer for
The BMJ provided helpful comments on interpretation of results
and limitations of the study, and the paper was revised
accordingly.With respect to dissemination, the patient reviewer
noted that the study findings could highlight for patients the
complexity of the issue and encourage them to discuss adherence
problems with their doctor to try to discover solutions. Lay
summaries associated with publication publicity will be created
and any consequent media opportunities to disseminate these
findings more widely will be taken up.
Results
We identified 570 337 patients with at least two statin
prescriptions during the study period and no statin prescription
in the 12 months previous to the study, 431 023 (76%) in the
primary prevention group and 139 314 (24%) in the secondary.
Overall, in the primary prevention group, with a median
follow-up time of 137 weeks, 204 622 (47%) discontinued statin
treatment and 147 305 (72% of those who discontinued)
restarted. In the secondary prevention group, with a median
follow-up time of 182 weeks, 57 791 (41%) discontinued and
43 211 (75% of those who discontinued) restarted (fig 1⇓).
Within the primary prevention group, 12 445 (3%) patients were
censored during follow-up because of a cardiovascular event.
Of these, 566 (4.5%) died within 90 days of diagnosis, 433
(3.5%) within 28 days. Of patients with a longer survival time,
7322 (62%) had a statin prescription within 28 days of their
diagnosis, 11 359 (96%) within two months.
Cohort description
In this article, we present results for the primary and secondary
prevention groups together to highlight similarities and
differences.When both prevention groups are involved, the first
number is for the primary group and the second for the
secondary group. During follow-up, the overall discontinuation
rates were 13 and 9.6 per 100 person years for the primary and
secondary prevention groups, respectively. After the first six
months, 19% and 13% had discontinued, after one year 27%
and 19%, and after two years 35% and 26% (fig 2⇓). For patients
discontinuing, restarting rates were 44 and 55 per 100 person
years and median gaps between discontinuation and restarting
were 36 weeks (interquartile range 18-108) and 29 weeks
(17-77)). Within the discontinuation group, 38% and 43%
restarted within six months of stopping, 55% and 61% within
one year, and 66% and 72% within two years (fig 3⇓).
Statin prescribing
Tables 1 and 2⇓ present descriptive statistics for the primary
and secondary groups, respectively. Most patients started
treatment using simvastatin (79% and 68% for the primary and
secondary prevention groups, respectively), with fewer starting
on atorvastatin (16% and 25%, respectively). Most users did
not switch statins (81% and 78%), but of those who did, 52%
and 49% changed to atorvastatin, and 28% and 33% to
simvastatin. At the time of stopping or leaving the cohort, 72%
and 63% were still on simvastatin, and 21% and 28% on
atorvastatin. Most restarters resumed on their most recently
prescribed statin (78% and 80%), but of the 22% and 20% who
changed statins, 42% and 37% switched to atorvastatin, and
29% and 37% to simvastatin. Among patients who restarted,
the most common drug was simvastatin (67% and 63%),
followed by atorvastatin (22% and 26%; supplementary tables
1 and 2).
In the analysis for discontinuation of statin treatment, type and
dose of statin were not important factors in the primary
prevention group (table 3⇓). In the secondary prevention group,
rosuvastatin use was associated with increased discontinuation
risk, and pravastatin use was associated with decreased risk
(both compared with simvastatin use; table 4⇓). Patients on a
lower statin dose were more likely to discontinue treatment,
and patients on a higher dose less likely to discontinue. For
patients restarting statin treatment in both the primary and
secondary prevention groups, type and dose of statin in the final
prescription before discontinuation were important factors
(tables 3 and 4⇓). Statins other than simvastatin were associated
with a decreased risk of restarting. Patients on a lower statin
dose were less likely to restart treatment, and patients on a higher
dose more likely to restart.
Factors associated with discontinuation of
statin treatment
Overall, patients in the primary prevention group were more
likely to discontinue with statin treatment than those in the
secondary prevention group (unadjusted hazard ratio 1.28 (95%
confidence interval 1.27 to 1.30), adjusted for sex and age 1.26
(1.24 to 1.27)).
Increased risks of discontinuation
Tables 3 and 4⇓ show the hazard ratios for associations between
the factors and discontinuation risk in primary and secondary
prevention groups, and figure 4⇓ presents the hazard ratios for
continuous variables in both groups. In the multivariate model
accounting for comorbidities, clinical values, and lifestyle
variables, factors associated with increased risk of
discontinuation in both the primary and secondary prevention
groups were:
• Age younger than 50 years (age 50 years v 60 years;
adjusted hazard ratio 1.16 (95% confidence interval 1.15
to 1.16) for primary prevention group, 1.11 (1.10 to 1.13)
for secondary prevention group)
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• Age 75 years or older (age 75 years v 60 years; 1.04 (1.03
to 1.05) for primary prevention group, 1.10 (1.08 to 1.12)
for secondary prevention group)
• Female sex
• Ethnic minority group (compared with white or
non-recorded patients)
• Relatively low body mass index (index of 20 v index of
25; 1.09 (1.08 to 1.11) for primary prevention group, 1.12
(1.10 to 1.14) for secondary prevention group)
• Current smoking (compared with non-smokers)
• Type 1 diabetes
• Chronic liver disease
• Chronic obstructive pulmonary disease
• Baseline total cholesterol/high density lipoprotein ratio
above 5 (ratio 5.25 v ratio 3.5; 1.11 (1.10 to 1.12) for
primary prevention group, 1.10 (1.08 to 1.12) for secondary
prevention group)
• Prescriptions for other treatments
• In patients who had used statins for more than 12 months,
dementia was associated with an increased risk of
subsequent discontinuation.
Factors associated with increased risk of discontinuation in the
secondary prevention group only were: atrial fibrillation; familial
hypercholesterolaemia (tables 3 and 4⇓, fig 4⇓).
Decreased risk of discontinuation
In both prevention groups, factors associated with decreased
risk of discontinuation of statin treatment were ex-smokers,
hypertension, and use of anticoagulant drugs. For the primary
prevention group only, these factors were type 2 diabetes, atrial
fibrillation, heart failure, and familial hypercholesterolaemia.
For the secondary prevention group only, aspirin use was
associated with decreased risk. In both groups, dementia was
associated with a decreased risk for the first 12 months of
follow-up.
Factors associated with restarting of statin
treatment
Overall, patients who had stopped taking statins in the primary
prevention group were less likely to restart statin treatment than
those in the secondary prevention group (unadjusted hazard
ratio 0.86 (95% confidence interval 0.84 to 0.87); adjusted
hazard ratio for sex and age 0.80 (0.79 to 0.81)).
Increased risk of restarting
In the multivariate model accounting for comorbidities, clinical
values, and lifestyle variables, factors associated with an
increased risk of restarting (that is, being more likely to restart)
in both the primary and secondary prevention groups were ethnic
minority groups (comparedwith white or non-recorded patients),
current smoking, and type 2 diabetes. Factors associated with
increased risk of restarting in the primary prevention group only
were type 1 diabetes, chronic obstructive pulmonary disease,
hypertension, family history of cardiovascular disease, and
familial hypercholesterolaemia. In the secondary prevention
group only, these factors were younger age, ex-smoking, and
aspirin use (tables 3 and 4⇓, fig 5⇓).
Decreased risk of restarting
Tables 3 and 4⇓ show the hazard ratios for associations between
the factors and risk of restarting in primary and secondary
prevention groups, and figure 5⇓ presents the hazard ratios for
continuous variables in both groups. Factors associated with a
decreased risk of restarting (less likely to restart) in both the
primary and secondary prevention groups were female sex, age
75 years or older (age 75 years v 60 years, adjusted hazard ratio
0.90 (95% confidence interval 0.89 to 0.91) for primary
prevention group, 0.86 (0.85 to 0.87) for secondary prevention
group), and dementia. Factors associated with a decreased risk
of restarting in the primary prevention group only were:
• Age 40 years or younger (age 40 years v 60 years, 0.96
(0.95 to 0.97))
• Cancer
• Aspirin use
• Anticoagulant use
• Relatively low body mass index (index 20 v index 25, 0.96
(0.95 to 0.97))
• Baseline total cholesterol:high density lipoprotein ratio
below 1.4 (ratio 1.4 v ratio 3.5, 0.90 (0.88 to 0.92)).
For the secondary prevention group only, the additional factor
was atrial fibrillation.
Categorised results summary
All of the associations between patient factors and increased,
decreased, or similar risks of discontinuation and restarting
statin treatment were categorised into three groups (table 5⇓):
• Patients who are more likely to discontinue and less likely
to restart—that is, elevated discontinuation and lowered
or neutral restarting, or neutral discontinuation and lowered
restarting (real stopping)
• Patients who are both more likely to discontinue and more
likely to restart—that is, elevated discontinuation and
elevated restarting (stopping-restarting)
• Patients who are less likely to discontinue or more likely
to restart—that is, lowered discontinuation and elevated
or neutral restarting, or neutral discontinuation and elevated
restarting (relative adherence).
Additional analyses
Terms of use
Statin discontinuation rates were much higher in the first year
of use (32 and 21 per 100 person years) than after the first year
of use (7.4 and 6.4 per 100 person years). Results from the
separate analyses for factors associated with discontinuation in
the first year of use and after the first year were all consistent
in both primary and secondary prevention groups for all factors,
apart from the finding for dementia described earlier
(supplementary table 3).
Second definition of discontinuation (12 month
gap)
We identified 384 025 patients with at least two years of
follow-up in the primary prevention group and 124 244 patients
in the secondary prevention group. Overall, in the primary
prevention group, with a median follow-up time of 235 weeks,
109 706 (29%) discontinued with a rate of 5.9 per 100 person
years and 49 570 (45% of those who discontinued) restarted. In
the secondary prevention group, with a medium of 282 weeks,
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27 071 (22%) discontinued with a rate of 3.8 per 100 patient
years and 13 319 (49% of those who discontinued) restarted the
treatment by the end of the study period (supplementary figs 1
and 2).
Factors associated with increased or decreased risks of
discontinuation and restarting were broadly consistent with the
main analysis. Only for black ethnicity and only in the primary
prevention group was the risk of discontinuation statistically
significant, but the risk of restarting did increase for all ethnic
minorities in the primary prevention group and for some in the
secondary prevention group. These results accord with those
from the main analysis (supplementary table 5, supplementary
figs 3 and 4).
Sensitivity analyses
In both prevention groups, inclusion of patients with only one
statin prescription resulted in higher overall rates of
discontinuation, with 228 240 (50%) and 60 638 (43%) of
patients discontinuing during the study period. The analysis of
factors associated with discontinuation, however, gave similar
results to the main analysis (supplementary table 6). Similar
results were also seen in the analysis with an observational
period ending not later than five years from the start of
treatment, as well as the analysis with a separate category for
unknown ethnicity (data not shown). Results from the analysis
run on subgroups of patients with known Townsend score were
in line with the main findings (supplementary table 4).
Discussion
In this large population based study, we used routinely collected
data from primary care to determine discontinuation and
restarting rates for statins, and to identify factors associated with
higher or lower likelihoods of discontinuation or restarting of
statin treatment. High rates of statin discontinuation have
commonly been reported, but our findings suggest that most
patients often described as “stoppers” might more accurately
be described as “non-adherent users.” This study identified three
broad categories of statin users within both primary and
secondary prevention groups: patients who are likely to
discontinue and not likely to restart (real stoppers), patients who
are likely to discontinue but likely to restart (stop-starters), and
patients who are less likely to discontinue or more likely to
restart (relative adherents).
Real stoppers
In the first category of real stoppers, factors occurring in both
prevention groups included women, older age, lower bodymass
index scores, chronic liver disease and multiple drugs. With
respect to older patients, a review has noted that other conditions
in the older population might affect statin metabolism or cause
similar side effects, thus changing the statin pharmacokinetics
for this group.27 In particular, muscular side effects have been
shown elsewhere to be important in older patients treated with
statins.28 The association between liver disease and increased
risk of discontinuation followed by decreased risk of restarting
could be related to statins causing an elevation of liver enzymes,
which might cause doctors to stop prescribing the drug.29 The
association between increased risk of discontinuation and the
number of other treatments used apart from those related to
cardiovascular treatment might result from patients having a
more serious condition according lower status to preventive
medications. Such patients also could be affected by the number
of drug treatments or have side effects from interactions between
drugs.
For the secondary prevention group only, patients with chronic
obstructive pulmonary disease and type 1 diabetes also seemed
more likely to be real stoppers. The finding for chronic
obstructive pulmonary disease seems to have no obvious
biological cause, conflicting with current biomedical research
that suggests statins are beneficial to such patients,30 and a recent
study showed decreased risk of exacerbations in statin users
with the disease.31 Our findings suggest that there are features
of having chronic obstructive pulmonary disease that make it
difficult to adhere to statin treatment, which need further
examination.
Increased risk of discontinuation in patients with type 1 diabetes
has not been observed in previous studies, but a recent
cross-sectional study on patients with type 1 diabetes32 showed
an association between statin use and impaired glycaemic
control. Although that study suggested revisiting insulin doses,
in real settings this might lead to a higher level of statin
discontinuation, and the increased risk of restarting statin
treatment found in the primary prevention group might also
suggest that this class of patients might be reintroduced to statins
after a precautionary break.
Some factors relate to more personal circumstances. For
example, relatively healthier patients (younger or with lower
body mass index) in the primary prevention group might prefer
to use other methods of lowering cardiovascular risk, such as
aspirin use or exercise. On the other hand, more frail patients
(older or those with serious comorbidities) might experience
more problematic side effects or drug interactions. Patients with
dementia could have particular problems in terms of treatment
decisions and maintenance as their condition worsens.
Stop-starters
Factors in this category notably differed from the real stopper
category, consisting primarily of patients with cultural or
lifestyle risk factors—people from ethnic minorities and current
smokers. Only two disease factors were included in this
category, both in the primary prevention group. For chronic
obstructive pulmonary disease, the increases in discontinuation
and decreases in restarting were quite low and might reflect
under-reporting in smoking status. For type 1 diabetes, where
disturbances in glycaemic control might cause occasional
adherence problems, the higher restarting risk might be partly
explained by regular consultations to review glycated
haemoglobin levels every three to six months at which statin
use might also be discussed. For younger patients in the
secondary prevention group, the stop-start tendency might be
explained similarly to real stopping for this group in the primary
group (but modified by experience of a past cardiovascular
event).
As a lifestyle factor, current smoking is not surprising in this
category because the dangers of this behaviour are well known
and it is likely to signal either a general lack of concern for
health issues or personal issues that have overwhelmed health
concerns. The more complex result is the inclusion in this
category across both prevention groups of ethnic minority status,
albeit with different levels of outcome across different
ethnicities. This could reflect a range of causes, whichmight—in
different mixes and levels in different ethnicities—be more
prevalent in some groups in the ethnic communities. Such factors
include communication issues, cultural issues including attitudes
to conventional medicine, and lifestyle issues.33 34
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Relative adherents
Factors in this category mostly relate to cardiovascular
conditions and the tendency to adherence is more pronounced
in the primary prevention group. These factors could relate to
a group of individuals at serious risk of cardiovascular events,
who are concerned to avoid such events, particularly relatively
younger or healthier patients in the primary prevention group.
Two factors appear in both prevention groups: hypertension and
use of anticoagulant drugs. In the primary prevention group
only, patients with type 2 diabetes or familial
hypercholesterolaemia showed similar lower risks of
discontinuation. In the secondary prevention group, aspirin users
also had lower risks of discontinuing. For both aspirin and
anticoagulants, the lower risk of discontinuation in the secondary
prevention group could point to increased treatmentmanagement
for people being treated for serious cardiovascular problems.
Other findings
In general, our study found few associations between the type
of statin used and poor adherence or stopping. We found no
difference between the drug type and discontinuation risk in the
primary group, and a 19% increased risk for rosuvastatin in the
secondary group compared with simvastatin. The prescribed
dose could reflect the severity of the existing cardiovascular
disease or higher cardiovascular risk score, so patients on smaller
doses were more likely to be real stoppers whereas patients on
higher ones were more likely to be adherent.
Comparisons with other studies
With respect to statin adherence, a review has identified three
groups of predictors: patient factors, physician factors, and
healthcare system factors.35But within the environment of freely
available national healthcare in the UK, the last of these
predictor groups is still largely irrelevant. The data source we
used has no information on physician behaviour but, given the
size and focus of our study, differences arising from patient
characteristics are likely to overwhelm effects arising from
doctor related issues. This study relates to patient issues, which
is the most complex aspect, potentially spanning physical and
psychological personal characteristics, genetic and other health
effects, cultural issues, and lifestyle choices. Our data source,
however, does not allow us to go further than examine
discontinuation and restarting rates associated with some of
these factors or proxies for them.
Discontinuation rate
In earlier studies, definitions of both discontinuation and
non-adherence have differed widely, creating a challenge for
several meta-analyses.15-36 One of these meta-analyses included
both randomised controlled trials and observational studies,15
showing that adherence levels at one year reported in
randomised controlled trials were on average much higher
(90.3% (95% confidence interval 89.9% to 90.8%)) than those
reported in observational studies (49% (48.9% to 49.2%)). In
our study, 75% of patients were still on statins by the end of the
first year.
Further comparisons are difficult because observational studies
have not been consistent in their design, with definition of
discontinuation varying from 30 days37 to 12 months.19 Studies
using reimbursement or dispensing data suggest lower adherence
estimates than studies based on prescribing data because patients
who receive prescriptions might not fill these at a pharmacy.
Several other minor differences between our study and others
probably reflect data selection issues such as patient age range
and data source (general population, insurance data, surveys,
or hospital discharges).
Discontinuation risk factors
Ameta-analysis based on observational studies used pharmacy
and insurance database refills, and included only studies with
validated adherence measures.16 It was designed to identify
reliable predictors of non-adherence to statins, combining results
from studies with different sets of available variables and
different definitions of non-adherence. This study did not
distinguish between primary and secondary prevention, but
diagnosis of cardiovascular disease, younger and older age,
female sex, and lower income were selected as factors in this
study, and our results broadly agree with these and other
outcomes. Regimen complexity, the relation between an
increasing number of non-cardiovascular treatments and low
adherence, gave similar results to our study, but the better
adherence association with hypertension and with diabetes (type
2 only in our study) was found only in our primary prevention
group.
Later observational studies were consistent with our results in
identifying discontinuation factors such as diagnosis of
cardiovascular disease,38 female sex,33 38 younger and older age,26
smoking,34 and normal weight.39 Our findings of increased
discontinuation risks for ethnic minorities agree with results
from another Danish study33 and an Australian study,34 which
reported increased risks in patients using a language other than
English at home.
Restarting
Most of the existing studies looked only at factors associated
with discontinuation, and only a few investigated the process
of restarting. In a Canadian study, 54% of statin users
discontinued the treatment but 57% of these restarted.17 In our
study, despite the longer study period, the proportion of
discontinuers was slightly lower (46%) and the proportion of
restarters was higher (73%). The difference might be explained
by timing, because the Canadian study was conducted on data
between 1997 and 2004, when there was less evidence to support
the use of statins. The study also concentrated on adverse events
or visits to physicians as possible factors for restarting and did
not investigate any patient level characteristics by incorporating
them in the design.
Another study in the USA, similar to ours, considered restarting
and showed that younger age and female sex were associated
both with increased risk of discontinuation and decreased risk
of restarting.18 Zhang and colleagues19 investigated the reasons
for discontinuation among 57 292 patients of an original cohort
of 107 835 statin users. The proportion of patients who
discontinued was 53%, which was much higher than in our
study despite their longer 12 month gap for discontinuation,
while the proportion of those restarting was 64%, which was
similar to our study. Unlike our study, Zhang and colleagues
did not attempt to identify groups of patients more likely to
discontinue or to restart.
Strengths and limitations
This large study was based on a representative sample of statin
users from the general population. The size and rigorous design
has facilitated investigation of several factors identified in
previous studies and meta-analyses within a single coherent
structure. With separate information for the primary and
secondary prevention groups, and a long period of follow-up,
the study delivers valuable information about various issues, in
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particular the less studied aspect of discontinuation and restarting
rates, which gives a more comprehensive overview of statin
adherence.
There are several limitations related to our sources of
information. Information on statin use was limited to estimates
based on prescription data, so actual statin use might be
overestimated because some patients might not fill the
prescription in the pharmacy or, having received pills, actually
take them. Patients with one prescription only were excluded
from the main analysis, but it is possible that they started
treatment and discontinued during or after the first prescription.
Exclusion of these patients could have led to a slightly
underestimated rate of discontinuation. The definition of
discontinuation as a 90 day gap might also not capture patients
who discontinued for less than 90 days and then restarted.
Reasons for discontinuation could not be included because, if
recorded, this is usually in the form of free text, which was not
available to this study. Coded information relating to reasons
was available only for a few patients (<1%). Not all factors
previously identified as possibly relevant to discontinuation
were available. For example, frequent exercise, for which we
lacked information, is a way of decreasing cardiovascular risk
and could have a double effect on discontinuation—improved
health or increased risk of statin side effects such as myalgia.40
However, a Finnish survey (n=9285) did include physical
activity as a possible predictor, but found no significant
association with statin non-adherence in either primary or
secondary prevention groups.39Another study, which identified
smoking as a predictor of non-adherence (as we did), also
identified being employed, higher level of education, and
psychological distress, which we could not investigate.34
An important limitation was lack of information about patient
attitudes, especially with respect to preventive treatment for the
primary group.41 A survey conducted on patients who did not
fill their new statin prescription has shown that the most
common reasons for this were the decision to change their
lifestyle (63%) and a fear of side effects (53%).42 We also had
no information about physician characteristics or adherence to
guidelines, or about contacts between doctor and patient.
Implications
Because of the lack of data on reasons for discontinuations, this
study cannot directly determine why patients discontinue statin
treatments. What it does do with some certainty is identify
groups of patients where a shared risk factor is associated with
increased or decreased levels of discontinuation or restarting
compared with their reference group.
Although the risk factors in each broad category differ in detail
between the primary and secondary prevention groups, there is
a high degree of commonality. Some differences also clearly
reflect the varying circumstances faced by patients who are at
risk of a cardiovascular event compared with those who have
actually had one. All categories include useful information for
doctors and patients, and for researchers interested in more
detailed and focused studies using more complete or exact data
sources.
The first two categories of statin users—real stoppers and
stop-starters—are potentially of greatest interest and use. Across
both, doctors and patients could make use of information from
this study. Doctors could use the information to identify which
patients might need more help and encouragement to maintain
adherence. Our results could also highlight to patients that many
people like them or with their condition have tended to show
real stopping or stop-starting adherence patterns. Patients might
then be encouraged to discuss such issues with their doctor to
try to discover solutions, alternatives, or compromises that could
improve their adherence.
Researchers might also be interested in the outcomes from either
of these categories—particularly in those which are least easily
explained or where non-adherence for a patient might carry
most risks. In terms of stop-starting tendencies in somemembers
of ethnic communities, this evidence suggests several research
questions that either apply directly to adherence to statins or
other drugs, or as part of wider studies looking at ways of
spreading the potential benefits of NHS healthcare to sections
of the population who are more difficult to reach.
Conclusion
We have found that, although more than 40% of statin users do
discontinue their treatment at some point, more than 70% of the
discontinuers restart. We have also identified those patient
factors linked to discontinuation and restarting patterns, which
suggest relative adherence, real stopping, or stop-starting
behaviour. Our overall levels of restarting suggest that, with a
few exceptions, the problem of statin stopping could be part of
the wider issue of temporary stopping or poor adherence.
We have also identified those groups of patients, such as women,
whomight be less likely to restart once discontinued, which has
the potential to facilitate greater focus by clinicians on these
groups. Information on groups with high levels of both
discontinuation and restarting, such as patients from ethnic
minority groups, might also encourage better understanding by
clinicians of the issues. Findings relating to unexpected
discontinuation or adherence, such for patients with chronic
obstructive pulmonary disease, deserve further study. With
respect to ethnic minorities, our results suggest the need for
further qualitative research based on access to a broader range
of detailed social and cultural information to clarify the reasons
for this important outcome.
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What is already known on this topic
With regards to statin treatment, previous studies have shown relatively high levels of discontinuation or low levels of adherence
Several studies found that younger and older patients, women, ethnic minorities, smokers, patients with lower body mass index, and
patients without hypertension or diabetes have lower adherence to statin treatment
However, most studies were not representative of the general population and were inconsistent overall in terms of study design, definitions
of exposure, and outcome
What this study adds
In this large population based study, ethnic minority status, smoking, and type 1 diabetes were more associated with discontinuation;
but among patients who had discontinued, these factors were more associated with restarting, suggesting poor adherence to statin
treatment
Type 2 diabetes and hypertension were less associated with discontinuation; among patients who had discontinued, these factors were
more associated with restarting, suggesting good adherence to statin treatment
However, younger and older ages, female sex, and liver disease were more associated with discontinuation; among patients who had
discontinued, these factors were less associated with restarting—suggesting true discontinuation with statin treatment (or “real stopping”)
Data sharing: To guarantee the confidentiality of personal and health
information, only the authors have had access to the data during the
study. It will be possible to access the CPRD data after the publication
of the results, but only on premises of the University of Nottingham
according to the CPRD licence.
The lead author affirms that the manuscript is an honest, accurate, and
transparent account of the study being reported; that no important
aspects of the study have been omitted; and that any discrepancies
from the study as planned (and, if relevant, registered) have been
explained.
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Tables
Table 1| Discontinuation of statin treatment in primary prevention group. Descriptive statistics shown for all included patients, patients
who continued, patients who discontinued, and patients who restarted statin treatment. Data are No (%) of patients unless stated otherwise.
SD=standard deviation
Restarted (n=147 305)Discontinued (n=204 622)Continued (n=226 401)Initiated (n=431 023)
Age at study entry
14 627 (9.9)18 987 (9.3)12 303 (5.4)31 290 (7.3)<45 years
31 203 (21.2)40 579 (19.8)37 191 (16.4)77 770 (18.0)45-54 years
47 593 (32.3)63 647 (31.1)76 395 (33.7)140 042 (32.5)55-64 years
39 366 (26.7)56 855 (27.8)72 574 (32.1)129 429 (30.0)65-74 years
14 516 (9.9)24 554 (12.0)27 938 (12.3)52 492 (12.2)75-84 years
59.9 (11.4)60.8 (11.6)62.5 (10.4)61.7 (11.0)Mean (SD; years)
Sex
77 786 (52.8)105 309 (51.5)120 423 (53.2)225 732 (52.4)Men
69 519 (47.2)99 313 (48.5)105 978 (46.8)205 291 (47.6)Women
Ethnicity
96 516 (65.5)133 697 (65.3)144 238 (63.7)277 935 (64.5)Ethnicity recorded
139 549 (94.7)195 158 (95.4)220 234 (97.3)415 392 (96.4)White or not recorded
2160 (1.5)2576 (1.3)1730 (0.8)4306 (1.0)Indian
944 (0.6)1114 (0.5)672 (0.3)1786 (0.4)Pakistani
319 (0.2)377 (0.2)265 (0.1)642 (0.1)Bangladeshi
884 (0.6)1098 (0.5)783 (0.3)1881 (0.4)Other Asian
721 (0.5)901 (0.4)457 (0.2)1358 (0.3)Black African
1044 (0.7)1249 (0.6)633 (0.3)1882 (0.4)Black Caribbean
257 (0.2)336 (0.2)283 (0.1)619 (0.1)Chinese
1427 (1.0)1813 (0.9)1344 (0.6)3157 (0.7)Other ethnic group
Smoking status
147 254 (100)204 505 (99.9)226 287 (99.9)430 792 (99.9)Patients with smoking status recorded
72 160 (49.0)100 965 (49.3)112 101 (49.5)213 066 (49.4)Non-smoker
42 114 (28.6)59 506 (29.1)73 179 (32.3)132 685 (30.8)Ex-smoker
6569 (4.5)8826 (4.3)8636 (3.8)17 462 (4.1)Light smoker
17 189 (11.7)23 127 (11.3)22 087 (9.8)45 214 (10.5)Moderate smoker
9222 (6.3)12 081 (5.9)10 284 (4.5)22 365 (5.2)Heavy smoker
Clinical measurements
143 475 (97.4)198 704 (97.1)220 599 (97.4)419 303 (97.3)Patients with body mass index recorded
29.0 (5.5)28.8 (5.5)29.0 (5.5)28.9 (5.5)Body mass index (mean (SD))
147 264 (100)204 533 (100)226 358 (100)430 891 (100)Patients with systolic blood pressure recorded
140.5 (18.4)140.5 (18.5)141.5 (18.2)141.0 (18.3)Systolic blood pressure (mean (SD))
92 820 (63.0)131 135 (64.1)152 720 (67.5)283 855 (65.9)Patients with ratio recorded
4.5 (1.5)4.5 (1.5)4.3 (1.5)4.4 (1.5)Total cholesterol:high density lipoprotein ratio (mean (SD))
Chronic conditions
2256 (1.5)3225 (1.6)3459 (1.5)6684 (1.6)Rheumatoid arthritis
1039 (0.7)1503 (0.7)1413 (0.6)2916 (0.7)Chronic renal disease
708 (0.5)1029 (0.5)988 (0.4)2017 (0.5)Liver disease
4766 (3.2)7028 (3.4)8266 (3.7)15 294 (3.5)Chronic obstructive pulmonary disease
9670 (6.6)14 814 (7.2)17 551 (7.8)32 365 (7.5)Cancer
3641 (2.5)5711 (2.8)8043 (3.6)13 754 (3.2)Atrial fibrillation
68 418 (46.4)95 059 (46.5)122 573 (54.1)217 632 (50.5)Hypertension
1338 (0.9)2124 (1.0)2954 (1.3)5078 (1.2)Heart failure
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Table 1 (continued)
Restarted (n=147 305)Discontinued (n=204 622)Continued (n=226 401)Initiated (n=431 023)
4632 (3.1)5540 (2.7)4420 (2.0)9960 (2.3)Type 1 diabetes
35 359 (24.0)44 510 (21.8)56 338 (24.9)100 848 (23.4)Type 2 diabetes
282 (0.2)639 (0.3)990 (0.4)1629 (0.4)Dementia
Genetic characteristics
10 731 (7.3)14 576 (7.1)16 158 (7.1)30 734 (7.1)Family history of premature coronary heart disease
504 (0.3)665 (0.3)699 (0.3)1364 (0.3)Familial hypercholesterolaemia
Use of other treatments
33 316 (22.6)48 276 (23.6)54 467 (24.1)102 743 (23.8)Aspirin
3150 (2.1)4876 (2.4)7030 (3.1)11 906 (2.8)Anticoagulants
2.0 (1.6)2.1 (1.6)2.0 (1.6)2.0 (1.6)No of other non-cardiovascular treatments
QRISK2 score
13 368 (9.1)18 589 (9.1)11 473 (5.1)30 062 (7.0)0-4%
21 032 (14.3)28 264 (13.8)25 802 (11.4)54 066 (12.5)5-9%
21 279 (14.4)28 598 (14.0)30 897 (13.6)59 495 (13.8)10-14%
19 877 (13.5)26 817 (13.1)31 541 (13.9)58 358 (13.5)15-19%
17 124 (11.6)23 391 (11.4)28 629 (12.6)52 020 (12.1)20-24%
54 625 (37.1)78 963 (38.6)98 059 (43.3)177 022 (41.1)25-99%
22.9 (16.0)23.5 (16.4)25.4 (16.0)24.5 (16.2)Mean (SD; %)
Townsend score (patient based)
91 036 (61.8)126 568 (61.9)139 487 (61.6)266 055 (61.7)Patients with data recorded
21 580 (14.6)30 465 (14.9)34 761 (15.4)65 226 (15.1)Group 1 (most affluent)
20 684 (14.0)29 440 (14.4)33 141 (14.6)62 581 (14.5)Group 2
18 666 (12.7)26 193 (12.8)28 522 (12.6)54 715 (12.7)Group 3
17 653 (12.0)24 135 (11.8)26 496 (11.7)50 631 (11.7)Group 4
12 453 (8.5)16 335 (8.0)16 567 (7.3)32 902 (7.6)Group 5 (most deprived)
Townsend score (practice based)
26 508 (18.0)37 078 (18.1)40 086 (17.7)77 164 (17.9)Group 1 (most affluent)
28 114 (19.1)39 007 (19.1)42 737 (18.9)81 744 (19.0)Group 2
29 242 (19.9)41 154 (20.1)46 375 (20.5)87 529 (20.3)Group 3
32 570 (22.1)45 204 (22.1)49 729 (22.0)94 933 (22.0)Group 4
30 871 (21.0)42 179 (20.6)47 474 (21.0)89 653 (20.8)Group 5 (most deprived)
Statin use at baseline
114 281 (77.6)161 135 (78.7)181 249 (80.1)342 384 (79.4)Simvastatin
25 975 (17.6)34 199 (16.7)35 655 (15.7)69 854 (16.2)Atorvastatin
3505 (2.4)4641 (2.3)4767 (2.1)9408 (2.2)Pravastatin
2985 (2.0)3923 (1.9)4014 (1.8)7937 (1.8)Rosuvastatin
559 (0.4)724 (0.4)716 (0.3)1440 (0.3)Fluvastatin
Statin dose at baseline (potency units)
18 969 (12.9)25 901 (12.7)25 929 (11.5)51 830 (12.0)Less than 1
65 015 (44.1)88 726 (43.4)94 815 (41.9)183 541 (42.6)One
61 613 (41.8)87 598 (42.8)103 025 (45.5)190 623 (44.2)Two
1708 (1.2)2397 (1.2)2632 (1.2)5029 (1.2)Three and more
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Table 2| Discontinuation of statin treatment in secondary prevention group. Descriptive statistics shown for all included patients, patients
who continued, who discontinued, and patients who restarted statin treatment. Data are no (%) of patients unless stated otherwise.
SD=standard deviation
Restarted (n=43 211)Discontinued (n=57 791)Continued (n=81 523)Initiated (n=139 314)
Age at study entry
1629 (3.8)1991 (3.4)2167 (2.7)4158 (3.0)<45 years
5063 (11.7)6128 (10.6)8923 (10.9)15 051 (10.8)45-54 years
10 236 (23.7)12 625 (21.8)19 995 (24.5)32 620 (23.4)55-64 years
13 580 (31.4)17 942 (31.0)26 113 (32.0)44 055 (31.6)65-74 years
12 703 (29.4)19 105 (33.1)24 325 (29.8)43 430 (31.2)75-84 years
66.8 (11.3)67.7 (11.2)67.2 (10.8)67.4 (11.0)Mean (SD; years)
Sex
24 472 (56.6)32 132 (55.6)50 353 (61.8)82 485 (59.2)Men
18 739 (43.4)25 659 (44.4)31 170 (38.2)56 829 (40.8)Women
Ethnicity
29 332 (67.9)39 092 (67.6)54 495 (66.8)93 587 (67.2)Ethnicity recorded
41 961 (97.1)56 273 (97.4)79 986 (98.1)136 259 (97.8)White or not recorded
394 (0.9)474 (0.8)479 (0.6)953 (0.7)Indian
174 (0.4)204 (0.4)218 (0.3)422 (0.3)Pakistani
50 (0.1)54 (0.1)67 (0.1)121 (0.1)Bangladeshi
102 (0.2)123 (0.2)106 (0.1)229 (0.2)Other Asian
69 (0.2)86 (0.1)79 (0.1)165 (0.1)Black African
187 (0.4)222 (0.4)146 (0.2)368 (0.3)Black Caribbean
41 (0.1)52 (0.1)71 (0.1)123 (0.1)Chinese
233 (0.5)303 (0.5)371 (0.5)674 (0.5)Other ethnic group
Smoking status
43 194 (100.0)57 754 (99.9)81 479 (99.9)139 233 (99.9)Patients with smoking status recorded
18 350 (42.5)25 121 (43.5)34 565 (42.4)59 686 (42.8)Non-smoker
16 445 (38.1)22 037 (38.1)34 288 (42.1)56 325 (40.4)Ex-smoker
2020 (4.7)2533 (4.4)3157 (3.9)5690 (4.1)Light smoker
4324 (10.0)5529 (9.6)6752 (8.3)12 281 (8.8)Moderate smoker
2055 (4.8)2534 (4.4)2717 (3.3)5251 (3.8)Heavy smoker
Clinical measurements
41 982 (97.2)55 801 (96.6)78 635 (96.5)134 436 (96.5)Patients with body mass index recorded
27.7 (5.2)27.5 (5.2)27.7 (5.0)27.6 (5.1)Body mass index (mean (SD))
43 209 (100)57 775 (100.0)81508 (100.0)139 283 (100)Patients with systolic blood pressure recorded
138.7 (20.2)138.7 (20.2)137.1 (20.4)137.8 (20.3)Systolic blood pressure (mean (SD))
20 679 (47.9)28 154 (48.7)42 124 (51.7)70 278 (50.4)Patients with ratio recorded
3.9 (1.3)3.9 (1.3)3.8 (1.3)3.8 (1.3)Total cholesterol:high density lipoprotein ratio (mean (SD))
Chronic conditions
930 (2.2)1287 (2.2)1663 (2.0)2950 (2.1)Rheumatoid arthritis
331 (0.8)508 (0.9)623 (0.8)1131 (0.8)Chronic renal disease
245 (0.6)352 (0.6)405 (0.5)757 (0.5)Liver disease
3030 (7.0)4166 (7.2)4892 (6.0)9058 (6.5)Chronic obstructive pulmonary disease
4077 (9.4)5998 (10.4)8092 (9.9)14 090 (10.1)Cancer
3388 (7.8)5061 (8.8)7030 (8.6)12 091 (8.7)Atrial fibrillation
19 723 (45.6)26 786 (46.3)36 824 (45.2)63 610 (45.7)Hypertension
2397 (5.5)3524 (6.1)5169 (6.3)8693 (6.2)Heart failure
535 (1.2)696 (1.2)805 (1.0)1501 (1.1)Type 1 diabetes
4949 (11.5)6614 (11.4)8858 (10.9)15 472 (11.1)Type 2 diabetes
220 (0.5)436 (0.8)729 (0.9)1165 (0.8)Dementia
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Table 2 (continued)
Restarted (n=43 211)Discontinued (n=57 791)Continued (n=81 523)Initiated (n=139 314)
Genetic characteristics
2537 (5.9)3276 (5.7)4800 (5.9)8076 (5.8)Family history of premature coronary heart disease
20 (0.0)27 (0.0)19 (0.0)46 (0.0)Familial hypercholesterolaemia
Use of other treatments
30 179 (69.8)40 462 (70.0)60 684 (74.4)101 146 (72.6)Aspirin
3023 (7.0)4390 (7.6)6354 (7.8)10 744 (7.7)Anticoagulants
2.4 (1.6)2.4 (1.6)2.3 (1.6)2.3 (1.6)No of other non-cardiovascular treatments
Townsend score (patient based)
26 092 (60.4)35 111 (60.8)49 293 (60.5)84 404 (60.6)Patients with data recorded
5613 (13.0)7680 (13.3)11 286 (13.8)18 966 (13.6)Group 1 (most affluent)
5922 (13.7)8156 (14.1)11 491 (14.1)19 647 (14.1)Group 2
5439 (12.6)7361 (12.7)10 544 (12.9)17 905 (12.9)Group 3
5503 (12.7)7259 (12.6)9639 (11.8)16 898 (12.1)Group 4
3615 (8.4)4655 (8.1)6333 (7.8)10 988 (7.9)Group 5 (most deprived)
Townsend score (practice based)
7057 (16.3)9488 (16.4)13 399 (16.4)22 887 (16.4)Group 1 (most affluent)
7811 (18.1)10 391 (18.0)14 988 (18.4)25 379 (18.2)Group 2
8673 (20.1)11 829 (20.5)16 669 (20.4)28 498 (20.5)Group 3
10 002 (23.1)13 379 (23.2)18 752 (23.0)32 131 (23.1)Group 4
9668 (22.4)12 704 (22.0)17 715 (21.7)30 419 (21.8)Group 5 (most deprived)
Statin use at baseline
29 194 (67.6)39 600 (68.5)55 598 (68.2)95 198 (68.3)Simvastatin
10 405 (24.1)13 502 (23.4)20 653 (25.3)34 155 (24.5)Atorvastatin
2446 (5.7)3202 (5.5)3656 (4.5)6858 (4.9)Pravastatin
802 (1.9)1037 (1.8)1199 (1.5)2236 (1.6)Rosuvastatin
364 (0.8)450 (0.8)417 (0.5)867 (0.6)Fluvastatin
Statin dose at baseline (potency units)
6210 (14.4)8195 (14.2)8202 (10.1)16 397 (11.8)Less than 1
18 315 (42.4)24 069 (41.6)28 090 (34.5)52 159 (37.4)One
16 826 (38.9)23 003 (39.8)37 509 (46.0)60 512 (43.4)Two
1860 (4.3)2524 (4.4)7722 (9.5)10 246 (7.4)Three and more
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Table 3| Adjusted hazard ratios for discontinuation and restarting statin treatment in primary prevention group
Adjusted hazard ratio (95% CI)
Restarting†Discontinuation*
Sex
ReferenceReferenceMen
0.92 (0.91 to 0.93)1.06 (1.05 to 1.07)Women
Ethnicity
ReferenceReferenceWhite or not recorded
1.30 (1.24 to 1.37)1.45 (1.39 to 1.52)Indian
1.29 (1.20 to 1.39)1.48 (1.39 to 1.58)Pakistani
1.46 (1.29 to 1.65)1.18 (0.99 to 1.41)Bangladeshi
1.26 (1.19 to 1.34)1.37 (1.26 to 1.49)Other Asian
1.30 (1.19 to 1.41)1.89 (1.72 to 2.08)Black African
1.30 (1.22 to 1.39)1.89 (1.74 to 2.04)Black Caribbean
1.26 (1.12 to 1.43)1.25 (1.11 to 1.41)Chinese
1.21 (1.14 to 1.29)1.36 (1.28 to 1.44)Other ethnic group
Smoking status
ReferenceReferenceNon-smoker
1.00 (0.98 to 1.01)0.97 (0.96 to 0.98)Ex-smoker
1.09 (1.06 to 1.12)1.07 (1.04 to 1.09)Light smoker
1.05 (1.04 to 1.07)1.10 (1.08 to 1.12)Moderate smoker
1.05 (1.03 to 1.08)1.16 (1.13 to 1.19)Heavy smoker
Chronic conditions
1.01 (0.96 to 1.06)1.02 (0.99 to 1.06)Rheumatoid arthritis
1.04 (0.97 to 1.12)1.03 (0.98 to 1.08)Chronic renal disease
0.91 (0.85 to 0.98)1.17 (1.10 to 1.25)Liver disease
1.06 (1.03 to 1.10)1.04 (1.01 to 1.06)Chronic obstructive pulmonary disease
0.97 (0.95 to 0.99)1.02 (1.00 to 1.04)Cancer
0.98 (0.94 to 1.02)0.96 (0.93 to 0.99)Atrial fibrillation
1.08 (1.07 to 1.10)0.80 (0.79 to 0.81)Hypertension
1.01 (0.96 to 1.07)0.92 (0.88 to 0.97)Heart failure
1.15 (1.11 to 1.19)1.18 (1.15 to 1.22)Type 1 diabetes
1.35 (1.33 to 1.37)0.80 (0.78 to 0.81)Type 2 diabetes
—0.63 (0.56 to 0.71)Dementia, short term statin use‡
—1.14 (1.03 to 1.26)Dementia, long term statin use‡
0.80 (0.71 to 0.90)—Dementia in previous statin use
Genetic characteristics
1.04 (1.02 to 1.07)0.98 (0.96 to 1.00)Family history of premature coronary heart disease
1.23 (1.12 to 1.35)0.86 (0.80 to 0.93)Familial hypercholesterolaemia
Use of other treatments
0.92 (0.91 to 0.94)1.02 (1.01 to 1.04)Aspirin
0.94 (0.90 to 0.98)0.88 (0.85 to 0.91)Anticoagulants
1.00 (1.00 to 1.01)1.02 (1.02 to 1.03)Each of other non-cardiovascular treatment
Townsend score groups (patient based)§
ReferenceReference1 (most affluent)
0.99 (0.97 to 1.02)1.02 (1.00 to 1.04)2
1.00 (0.97 to 1.03)1.02 (1.00 to 1.05)3
1.02 (0.99 to 1.05)0.99 (0.96 to 1.02)4
1.08 (1.04 to 1.12)0.98 (0.95 to 1.02)5 (most deprived)
Statin use at baseline
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2016;353:i3305 doi: 10.1136/bmj.i3305 (Published 28 June 2016) Page 14 of 20
RESEARCH
Table 3 (continued)
Adjusted hazard ratio (95% CI)
Restarting†Discontinuation*
ReferenceReferenceSimvastatin
0.86 (0.85 to 0.88)0.99 (0.97 to 1.01)Atorvastatin
0.84 (0.81 to 0.88)0.98 (0.94 to 1.03)Pravastatin
0.81 (0.77 to 0.84)0.96 (0.91 to 1.02)Rosuvastatin
0.85 (0.78 to 0.94)1.00 (0.92 to 1.09)Fluvastatin
Statin dose at baseline (potency units)
0.89 (0.87 to 0.91)1.02 (1.00 to 1.04)Less than 1
ReferenceReferenceOne
1.11 (1.10 to 1.13)0.99 (0.98 to 1.01)Two
1.41 (1.36 to 1.45)1.01 (0.97 to 1.06)Three and more
All adjusted models include sex, ethnicity, smoking status, chronic conditions, use of other drugs, practice based Townsend score groups, and year of entering
the study.
*Model also includes type and dose of statin at baseline, fractional polynomials for age ((age/5)2 and (age/5)2ln(age/5)), body mass index (BMI; BMI−0.5, ln(BMI)),
total cholesterol:high density lipoprotein ratio (ln(ratio)), and systolic blood pressure (SBP; (SBP/10), (SBP/10)2). Practice ID was included as clustering variable.
†Model also includes type and dose of statin at discontinuation, fractional polynomials for age ((age/5)0.5, (age/5)3), body mass index (BMI−0.5), total cholesterol:high
density lipoprotein: ratio (ratio0.5), and systolic blood pressure ((SBP/10)3). Practice ID was included as clustering variable.
‡The analysis was stratified by dementia. Results for discontinuation were taken from additional analyses by terms of use (supplementary table 3).
§Estimates of Townsend score groups (patient based) are from the additional analysis (supplementary table 4).
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Table 4| Adjusted hazard ratios for discontinuation and restarting statin treatment in secondary prevention group
Adjusted hazard ratio (95% CI)
Restarting†Discontinuation*
Sex
ReferenceReferenceMen
0.93 (0.91 to 0.95)1.14 (1.12 to 1.17)Women
Ethnicity
ReferenceReferenceWhite or not recorded
1.40 (1.25 to 1.56)1.35 (1.23 to 1.49)Indian
1.13 (0.97 to 1.31)1.41 (1.19 to 1.66)Pakistani
1.58 (1.26 to 1.98)1.17 (0.84 to 1.61)Bangladeshi
1.41 (1.17 to 1.71)1.52 (1.30 to 1.79)Other Asian
1.15 (0.90 to 1.48)1.69 (1.33 to 2.16)Black African
1.35 (1.16 to 1.58)1.80 (1.54 to 2.10)Black Caribbean
1.22 (0.94 to 1.58)1.17 (0.87 to 1.57)Chinese
1.13 (1.00 to 1.29)1.23 (1.10 to 1.37)Other ethnic group
Smoking status
ReferenceReferenceNon-smoker
1.04 (1.02 to 1.06)0.96 (0.94 to 0.98)Ex-smoker
1.11 (1.06 to 1.16)1.14 (1.09 to 1.19)Light smoker
1.04 (1.01 to 1.08)1.20 (1.16 to 1.24)Moderate smoker
1.09 (1.04 to 1.14)1.27 (1.21 to 1.33)Heavy smoker
Chronic conditions
1.03 (0.97 to 1.10)1.02 (0.96 to 1.08)Rheumatoid arthritis
0.90 (0.81 to 0.99)1.08 (0.98 to 1.18)Chronic renal disease
0.93 (0.82 to 1.07)1.22 (1.09 to 1.36)Liver disease
1.03 (1.00 to 1.08)1.22 (1.18 to 1.27)Chronic obstructive pulmonary disease
0.96 (0.93 to 0.99)1.05 (1.03 to 1.08)Cancer
0.94 (0.90 to 0.98)1.05 (1.01 to 1.09)Atrial fibrillation
1.01 (0.99 to 1.03)0.94 (0.92 to 0.96)Hypertension
0.97 (0.93 to 1.01)0.97 (0.94 to 1.01)Heart failure
1.02 (0.93 to 1.10)1.17 (1.08 to 1.26)Type 1 diabetes
1.06 (1.02 to 1.09)0.97 (0.95 to 1.00)Type 2 diabetes
—0.71 (0.61 to 0.82)Dementia, short term statin use‡
—1.22 (1.08 to 1.39)Dementia, long term statin use‡
0.75 (0.65 to 0.86)—Dementia in previous statin use
Genetic characteristics
1.02 (0.97 to 1.06)1.00 (0.96 to 1.04)Family history of premature coronary heart disease
0.83 (0.54 to 1.29)1.74 (1.24 to 2.45)Familial hypercholesterolaemia
Use of other treatments
1.05 (1.02 to 1.07)0.83 (0.82 to 0.85)Aspirin
0.97 (0.93 to 1.02)0.89 (0.86 to 0.93)Anticoagulants
1.00 (0.99 to 1.00)1.03 (1.03 to 1.04)Each of other non-cardiovascular treatment
Townsend score groups (patient based)§
ReferenceReference1 (most affluent)
0.99 (0.94 to 1.03)1.02 (0.98 to 1.06)2
1.00 (0.95 to 1.05)0.99 (0.95 to 1.03)3
1.05 (1.00 to 1.10)1.02 (0.97 to 1.06)4
1.06 (1.00 to 1.12)0.97 (0.92 to 1.01)5 (most deprived)
Statin use at baseline
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Table 4 (continued)
Adjusted hazard ratio (95% CI)
Restarting†Discontinuation*
ReferenceReferenceSimvastatin
0.91 (0.88 to 0.93)1.00 (0.97 to 1.03)Atorvastatin
0.92 (0.87 to 0.97)0.94 (0.90 to 0.98)Pravastatin
0.77 (0.72 to 0.82)1.19 (1.11 to 1.28)Rosuvastatin
0.92 (0.81 to 1.04)1.09 (0.99 to 1.22)Fluvastatin
Statin dose at baseline (potency units)
0.88 (0.85 to 0.91)1.11 (1.08 to 1.14)Less than 1
ReferenceReferenceOne
1.12 (1.10 to 1.15)0.86 (0.84 to 0.88)Two
1.37 (1.31 to 1.42)0.60 (0.57 to 0.64)Three and more
All adjusted models include sex, ethnicity, smoking status, chronic conditions, use of other drugs, practice based Townsend score groups, and year of entering
the study.
*Model also includes type and dose of statin at baseline, fractional polynomials for age ((age/5) and (age/5)2), body mass index (BMI; ln(BMI), BMI0.5), total
cholesterol:high density lipoprotein ratio (ratio0.5), and systolic blood pressure (SBP; (SBP/10)−0.5).
†Model also includes type and dose of statin at discontinuation, fractional polynomials for age ((age/5)−1, (age/5)3), body mass index (BMI), total cholesterol:high
density lipoprotein ratio (ratio−0.5), and systolic blood pressure ((SBP/10)). Practice ID was included as clustering variable.
‡The analysis was stratified by dementia. Results for discontinuation were taken from additional analyses by terms of use (supplementary table 3).
For all models, Practice ID was included as clustering variable
§Estimates of Townsend score groups (patient based) are from the additional analysis (supplementary table 4).
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Table 5| Factors associated with increased and decreased risk of discontinuation and restarting of statin treatment. Data are percentage
change compared with the relevant reference group
Restarting statin treatmentDiscontinuation statin treatmentRisk factors
Primary prevention group
Patients more likely to discontinue and less likely to restart
−8%+6%Women v men
−23% to 0%+111 to +16%Age from 25 to 50 years v 60 years
−16% to −32%+4% to +29%Age from 75 to 84 years v 60 years
−12% to −1%+44% to +3%Body mass index from 15 to 23 v 25
—+17%Liver disease
−3%—Cancer
−20%+14%Dementia (long term statin use)
−8%+2%Aspirin use
—+2%Each other non-cardiovascular treatment
Patients more likely to discontinue and more likely to restart
+21% to +46%+25% to +89%Ethnic minority groups v white
+5% to +9%+7% to +16%Current smoking, from light to heavy v non-smoking
+6%+4%Chronic obstructive pulmonary disease
+15%+18%Type 1 diabetes
Patients less likely to discontinue or more likely to restart
—−3%Ex-smoking v non-smoking
—−4%Atrial fibrillation
+8%−20%Hypertension
—−8%Heart failure
+35%−20%Type 2 diabetes
+4%—Family history of heart disease
+23%−14%Familial hypercholesterolaemia
−6%−12%Anticoagulant use
Secondary prevention group
Patients more likely to discontinue and less likely to restart
−7%+14%Women v men
−14% to −26%+10% to +35%Age from 75 to 84 years v 60 years
—+55% to +3%Body mass index from 15 to 23 v 25
—+22%Liver disease
—+22%Chronic obstructive pulmonary disease
−4%+5%Cancer
−6%+5%Atrial fibrillation
—+17%Type 1 diabetes
—+22%Dementia (long term use)
—+74%Familial hypercholesterolaemia
—+3%Each other non-cardiovascular treatment
Patients more likely to discontinue and more likely to restart
+10% to +5%+166% to +11%Age from 25 to 50 v 60 years
+35% to +58%+23% to +80%Ethnic minority groups v white
+4% to +11%+14% to +27%Current smoking, from light to heavy v non-smoking
Patients less likely to discontinue or more likely to restart
+4%−4%Ex-smoking v non-smoking
—−6%Hypertension
+6%—Type 2 diabetes
+5%−17%Aspirin use
—−11%Anticoagulant use
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Figures
Fig 1 Flow chart of study patients discontinuing and restarting statin treatment, based on CPRD data
Fig 2 Patients who discontinued statin treatment, based on CPRD data, October 2014
Fig 3 Patients who restarted statins after discontinuation, based on CPRD data, October 2014
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Fig 4 Risk of discontinuation of statin treatment, as shown by fractional polynomials terms. Terms are for age (hazard ratios
compared with age 60 years), body mass index (hazard ratios compared with body mass index 25), high density lipoprotein
(HDL):total cholesterol ratio (hazard ratios compared with ratio 3.5), and systolic blood pressure (hazard ratios compared
with 130 mm Hg)
Fig 5Risk of restarting statin treatment, as shown by fractional polynomials terms. Terms are for age (hazard ratios compared
with age 60 years), body mass index (hazard ratios compared with body mass index 25), high density lipoprotein (HDL):total
cholesterol ratio (compared with ratio 3.5), and systolic blood pressure (compared with 130 mm Hg)
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